» Articles » PMID: 34944743

Unraveling Autocrine Signaling Pathways Through Metabolic Fingerprinting in Serous Ovarian Cancer Cells

Overview
Journal Biomedicines
Date 2021 Dec 24
PMID 34944743
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Focusing on defining metabolite-based inter-tumoral heterogeneity in ovarian cancer, we investigated the metabolic diversity of a panel of high-grade serous ovarian carcinoma (HGSOC) cell-lines using a metabolomics platform that interrogate 731 compounds. Metabolic fingerprinting followed by 2-dimensional and 3-dimensional principal component analysis established the heterogeneity of the HGSOC cells by clustering them into five distinct metabolic groups compared to the fallopian tube epithelial cell line control. An overall increase in the metabolites associated with aerobic glycolysis and phospholipid metabolism were observed in the majority of the cancer cells. A preponderant increase in the levels of metabolites involved in trans-sulphuration and glutathione synthesis was also observed. More significantly, subsets of HGSOC cells showed an increase in the levels of 5-Hydroxytryptamine, γ-aminobutyrate, or glutamate. Additionally, 5-hydroxytryptamin synthesis inhibitor as well as antagonists of γ-aminobutyrate and glutamate receptors prohibited the proliferation of HGSOC cells, pointing to their potential roles as oncometabolites and ligands for receptor-mediated autocrine signaling in cancer cells. Consistent with this role, 5-Hydroxytryptamine synthesis inhibitor as well as receptor antagonists of γ-aminobutyrate and Glutamate-receptors inhibited the proliferation of HGSOC cells. These antagonists also inhibited the three-dimensional spheroid growth of TYKNU cells, a representative HGSOC cell-line. These results identify 5-HT, GABA, and Glutamate as putative oncometabolites in ovarian cancer metabolic sub-type and point to them as therapeutic targets in a metabolomic fingerprinting-based therapeutic strategy.

Citing Articles

Targeting Oncometabolites in Peritoneal Cancers: Preclinical Insights and Therapeutic Strategies.

Nadhan R, Kashyap S, Ha J, Jayaraman M, Song Y, Isidoro C Metabolites. 2023; 13(5).

PMID: 37233659 PMC: 10222714. DOI: 10.3390/metabo13050618.


Understanding of Ovarian Cancer Cell-Derived Exosome Tropism for Future Therapeutic Applications.

Ren X, Kang C, Garcia-Contreras L, Kim D Int J Mol Sci. 2023; 24(9).

PMID: 37175872 PMC: 10179437. DOI: 10.3390/ijms24098166.


Complex metabolic interactions between ovary, plasma, urine, and hair in ovarian cancer.

Zhong X, Ran R, Gao S, Shi M, Shi X, Long F Front Oncol. 2022; 12:916375.

PMID: 35982964 PMC: 9379488. DOI: 10.3389/fonc.2022.916375.


Integrative analysis of plasma metabolomics and proteomics reveals the metabolic landscape of breast cancer.

An R, Yu H, Wang Y, Lu J, Gao Y, Xie X Cancer Metab. 2022; 10(1):13.

PMID: 35978348 PMC: 9382832. DOI: 10.1186/s40170-022-00289-6.


Comprehensive network analysis of dysregulated genes revealed MNX1-AS1/hsa-miR-4697-3p/HOXB13 axis in ovarian cancer chemotherapy response.

Wu A, Liu J, Zhang X, Niu C, Shu G, Yin G Cancer Sci. 2022; 113(8):2627-2641.

PMID: 35639251 PMC: 9357658. DOI: 10.1111/cas.15447.


References
1.
Scalise M, Console L, Rovella F, Galluccio M, Pochini L, Indiveri C . Membrane Transporters for Amino Acids as Players of Cancer Metabolic Rewiring. Cells. 2020; 9(9). PMC: 7565710. DOI: 10.3390/cells9092028. View

2.
Henriksen R, Dizeyi N, Abrahamsson P . Expression of serotonin receptors 5-HT1A, 5-HT1B, 5-HT2B and 5-HT4 in ovary and in ovarian tumours. Anticancer Res. 2012; 32(4):1361-6. View

3.
Sung H, Yang S, Ju W, Ahn J . Aberrant epigenetic regulation of GABRP associates with aggressive phenotype of ovarian cancer. Exp Mol Med. 2017; 49(5):e335. PMC: 5454450. DOI: 10.1038/emm.2017.62. View

4.
Bansal A, Simon M . Glutathione metabolism in cancer progression and treatment resistance. J Cell Biol. 2018; 217(7):2291-2298. PMC: 6028537. DOI: 10.1083/jcb.201804161. View

5.
Liang Y, Li H, Gan Y, Tu H . Shedding Light on the Role of Neurotransmitters in the Microenvironment of Pancreatic Cancer. Front Cell Dev Biol. 2021; 9:688953. PMC: 8363299. DOI: 10.3389/fcell.2021.688953. View